Phenylpropylaminopentane (-)-1-Phenyl-2-propylaminopentane (-)-PPAP CAS: 784118-64-5

CAS NO: 784118-64-5
Chemical Name :
Phenylpropylaminopentane
(-)-1-Phenyl-2-propylaminopentane
(-)-PPAP
Molecular Formula: C14H23N
CAS No.: 784118-64-5
Formula Weight: 205.35
CBNumber: CB43110641
Description Review
Description

PPAP, known by its chemical name (2-phenyl-4-piperidinyl) acetamide, is a synthetically derived compound that has gained attention for its various potential effects. With a molecular formula of C14H18N2O and formula weight of 230.31 g/mol, it is commonly indexed by its unique CAS number 784118-64-5. This article aims to explore the top ten keywords and synonyms from Google associated with PPAP, highlight its health benefits, potential effects, product mechanism, safety, side effects, and contraindications.

Top Ten Keywords and Synonyms:

  1. PPAP CAS 784118-64-5
  2. (2-phenyl-4-piperidinyl) acetamide
  3. PPAP synthesis techniques
  4. Pharmacological profile of PPAP
  5. PPAP supplements
  6. PPAP research and studies
  7. Natural alternatives to PPAP
  8. PPAP dosage and administration
  9. Long-term effects of PPAP
  10. Legality and regulations surrounding PPAP

Health Benefits of PPAP: While research is still ongoing, PPAP is believed to offer several potential health benefits. It has been suggested that PPAP may enhance cognitive function, improve focus and mental clarity, boost motivation, and increase energy levels. Additionally, preliminary studies indicate that PPAP may have neuroprotective properties, potentially making it a valuable tool in the prevention and treatment of neurodegenerative disorders.

Potential Effects: PPAP is often perceived as a nootropic, a substance that may enhance cognitive function. Users have reported increased alertness, better memory recall, and improved productivity. Some individuals have even compared the effects to those of stimulants, but without the associated jitters or crashes. However, it is important to note that individual experiences may vary, and more research is needed to fully understand the extent and scope of PPAP's effects.

Product Mechanism: PPAP is hypothesized to work by increasing the levels of dopamine and noradrenaline in the brain. By doing so, it may enhance synaptic transmission, leading to improved focus and mental performance. Its unique mechanism of action distinguishes it from other nootropic compounds, making it an area of interest for researchers.

Safety and Side Effects: At present, there are limited studies on the long-term safety profile of PPAP. Like any substance, it is crucial to exercise caution and adhere to recommended dosage guidelines. While PPAP is generally well-tolerated, potential side effects may include mild headaches, gastrointestinal discomfort, dizziness, or increased heart rate. As with any new supplement, it is advised to consult with a healthcare professional before use, especially for individuals with pre-existing medical conditions or those taking medications.

Contraindications: PPAP is not recommended for individuals who are pregnant or nursing. Furthermore, individuals with a history of cardiovascular conditions, high blood pressure, anxiety disorders, or sensitivity to stimulants should exercise caution. It is always advisable to consult with a medical professional before incorporating PPAP or any new compound into your routine.

Conclusion: PPAP, also known by its chemical name (2-phenyl-4-piperidinyl) acetamide, holds promise as a cognitive enhancer. Despite its growing popularity, it is vital to approach the use of PPAP with careful consideration. While it may provide short-term cognitive benefits, the long-term effects and safety profile necessitate further research. As such, it is recommended to consult with a healthcare professional to make informed decisions about incorporating PPAP or any supplements into your routine. As research evolves, our understanding of PPAP's potential benefits and effects will become clearer, leading to more informed discussions about its usage and impact on human cognition.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code